Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens

1 Mar 2017

Abstract excerpt

Telavancin (TD-6424), a semisynthetic lipoglycopeptide vancomycin-derivative, is a novel antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration (USFDA) had approved telavancin in 2009 for the treatment of complicated skin and skin structure infections (cSSSIs)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Resistance in Staphylococcus
Share to Bacterial Identification and Susceptibility Testing
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28634536
DOI: 10.1177/2049936117690501

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensPMID 28634536Read ↗

Activity of Telavancin against <i>S. aureus</i> isolated from cystic fibrosis patients including those with decreased susceptibility to CeftarolineSemantic proximity Read ↗

From Vancomycin to Oritavancin: The Discovery and Development of a Novel Lipoglycopeptide AntibioticSemantic proximity Read ↗

Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing MethodSemantic proximity Read ↗

Old and New Glycopeptide Antibiotics: Action and ResistanceSemantic proximity Read ↗

New Gram-Positive Agents: the Next Generation of Oxazolidinones and LipoglycopeptidesSemantic proximity Read ↗

Resisting the resistance: the antimicrobial peptide DGL13K selects for small colony variants of Staphylococcus aureus that show increased resistance to its stereoisomer LGL13K, but not to DGL13K.Semantic proximity Read ↗

Tripterhyponoid A from Tripterygium hypoglaucum Inhibiting MRSA by Multiple MechanismsSemantic proximity Read ↗

Comparativein vitroactivity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococciSemantic proximity Read ↗

Exposure to the antimicrobial peptides LL-37 and ATRA-1 induces a lipidome response in <i>Staphylococcus aureus</i> that alters membrane biophysical propertiesSemantic proximity Read ↗

Antibacterial Activity of Ethanolic Extract of Cardiospermum halicacabum against Methicillin-Resistant Staphylococcus aureusSemantic proximity Read ↗

Flavonolignans from silymarin modulate antibiotic resistance and virulence in Staphylococcus aureusSemantic proximity Read ↗

Specific Inhibition of VanZ-Mediated Resistance to Lipoglycopeptide AntibioticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.